Long-serving senior executive of lepu medical technology resigns, can the second generation successor stop the decline in performance? | Express announcement

①Tonight, lepu medical technology announced that General Manager Zhang Zhibin and Deputy General Manager Zheng Guorui resigned, and the Chairman's daughter Pu Fei took over as General Manager, with a "sea turtle elite" background; ②Starting from 2023, lepu medical technology's performance has declined for several consecutive quarters, and the market cap has dropped by one quarter compared to its peak period.

cls.cnSep 25 11:34 ET

Humanwell healthcare's "autumn of many events": Controlling shareholder is being applied for reorganization, previously penalized by regulators | Speed Reading Notice

1. Tonight, humanwell healthcare announced that its controlling shareholder Contemporary Technology has applied for restructuring, which has been accepted, there is a possibility of a change in control of humanwell healthcare; 2. Humanwell healthcare, its controlling shareholder Contemporary Technology, and the actual controller have been repeatedly monitored and sanctioned by regulatory authorities; 3. Earlier this year, executives of humanwell healthcare have successively reduced their shareholding, and the 2024H1 performance continues the trend of 'increased revenue but not increased profit' from 2023.

cls.cnSep 24 09:53 ET

Jiangsu Sihuan Bioengineering's actual controller has been given a "red card" for lifetime market ban again, and Lu Keping and his son are expected to be fined nearly 30 million yuan. Read the announcement quickly.

①Due to the ST Weichuang suspected of illegal disclosure of information, jiangsu sihuan bioengineering's ultimate controller Lu Keping and the company's director Lu Yu father and son received a "sky-high" fine. ②In this case, Lu Keping has issues such as keeping the identity of the ultimate controller "secret" and has once again been subjected to a lifetime ban from the securities market. ③According to the pre-notification of administrative penalties, Lu Keping and his son were fined a total of nearly 30 million yuan.

cls.cnSep 18 19:13 ET

How will Sansure Biotech Inc.'s performance in the first half of the year be impacted by its respiratory products and its second curve strategy? | Earnings conference

①Sansure Biotech Inc. director Dai Lizhong revealed at the earnings conference that the respiratory product revenue for the first half of 2024 is basically on par with the total for the entire previous year. ②The sales of respiratory products exceeded 0.4 billion yuan last year, and the overall revenue for the first half of this year is approximately 0.72 billion yuan. Based on this calculation, the proportion of respiratory product revenue is about 56%.

cls.cnSep 18 03:12 ET

Contec Medical Systems: Will increase layout efforts in Africa, and multiple in-vitro diagnostic products are expected to be registered within the year.|Focus on the earnings conference

① The decline in performance in the first half of the year is attributed to a reduction in orders due to downstream customers destocking and a high base from the previous year; ② Currently, bulk production of zirconia ceramic blocks for all-ceramic dentures has been achieved, and multiple ex vivo diagnostic products have entered the late stage of development, with registration expected to be completed within the year; ③ The company has made market breakthroughs in several countries in Africa and will continue to focus on the African market, increasing product distribution and marketing efforts.

cls.cnSep 12 10:33 ET

Overseas income has been declining year after year, zhejiang orient gene biotech sets up a new subsidiary to seek the Southeast Asian market.

①Zhejiang Orient Gene Biotech expands its wholesale trade business of medical instruments by establishing a new company in the Philippines, and expands its market in Southeast Asia and South Asia. ②Currently, Zhejiang Orient Gene Biotech's key overseas markets are mainly in the Americas and Europe, but in recent years, the revenue from overseas markets has been rapidly declining.

cls.cnSep 12 03:07 ET